In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The price of Zymeworks BC Inc (NASDAQ: ZYME) closed at $11.62 in the last session, down -2.43% from day before closing price of $11.91. In other words, the price has decreased by -$2.43 from its previous closing price. On the day, 0.68 million shares were traded. ZYME stock price reached its highest trading level at $12.05 during the session, while it also had its lowest trading level at $11.489.
Ratios:
We take a closer look at ZYME’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.40 and its Current Ratio is at 3.40. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.
On November 07, 2024, Leerink Partners Upgraded its rating to Outperform which previously was Market Perform and also upped its target price recommendation from $10 to $25.
Wells Fargo Downgraded its Overweight to Equal Weight on November 01, 2024, while the target price for the stock was maintained at $12.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 25 ’25 when EcoR1 Capital, LLC bought 53,501 shares for $12.91 per share. The transaction valued at 690,452 led to the insider holds 17,211,303 shares of the business.
EcoR1 Capital, LLC bought 43,848 shares of ZYME for $536,857 on Mar 26 ’25. The Director now owns 17,255,151 shares after completing the transaction at $12.24 per share. On Mar 20 ’25, another insider, EcoR1 Capital, LLC, who serves as the Director of the company, bought 73,476 shares for $12.93 each. As a result, the insider paid 949,883 and bolstered with 17,104,080 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZYME now has a Market Capitalization of 808483520 and an Enterprise Value of 601241408. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.68 while its Price-to-Book (P/B) ratio in mrq is 2.39. Its current Enterprise Value per Revenue stands at 7.88 whereas that against EBITDA is -5.32.
Stock Price History:
The Beta on a monthly basis for ZYME is 1.17, which has changed by 0.20664585 over the last 52 weeks, in comparison to a change of 0.08089435 over the same period for the S&P500. Over the past 52 weeks, ZYME has reached a high of $17.70, while it has fallen to a 52-week low of $7.97. The 50-Day Moving Average of the stock is -13.86%, while the 200-Day Moving Average is calculated to be -7.62%.
Shares Statistics:
According to the various share statistics, ZYME traded on average about 529.25K shares per day over the past 3-months and 581380 shares per day over the past 10 days. A total of 68.96M shares are outstanding, with a floating share count of 67.30M. Insiders hold about 4.07% of the company’s shares, while institutions hold 97.46% stake in the company. Shares short for ZYME as of 1741910400 were 5415327 with a Short Ratio of 10.23, compared to 1739491200 on 3837127. Therefore, it implies a Short% of Shares Outstanding of 5415327 and a Short% of Float of 10.100000000000001.
